Abstract Library

#4185 Primary hepatic neuroendocrine neoplasms – Clinical characteristics and treatment outcomes of a rare disease

Introduction: Liver involvement in Neuroendocrine Neoplasms (NEN) most commonly encompasses metastases from other organs or from an unknown primary. The current WHO classification defines primary hepatic NEN (PHNEN) as a distinct entity. With only few cases of PHNEN reported and difficulty to discern them from hepatic metastases, evidence on optimal management is very limited.

Conference:

Presenting Author:

Authors: Apostolidis L, Kender Z, Flegka V, Winkler E, Krug S,

Keywords: hepatic NEN, liver NEN, PHNEN,

#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)

Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weber M

Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,

Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,

#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro

Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Krug S

Authors: Krug S, Gress T, Theuerkorn K, Mordhorst J, Michl P,

Keywords: SSA, targeted therapies, SSTR,

#1403 A Univariate Analysis of Factors Influencing Survival in Advanced Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Jann H

Authors: Jimenez-Fonseca P, Monleón Getino A, Krug S, Fierro Maya F, Tamagno G,

Keywords: pNET, prognosis,

#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor

Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Krug S

Authors: Krug S, Tamagno G, Jann H, Jimenez-Fonseca P, Costa F,

Keywords: pNET,